DTx Pharma
Latest round
- Series B
Last raised
- Feb 2021
Total raised
- $115M
Investors
- 12
About DTx Pharma
Based in California, US, and founded in 2017, DTx Pharma, Inc. operates as a biotechnology company that develops RNA-based therapeutics to treat genetic drivers of diseases. The company was founded by Arthur Suckow, John Grund, and Adam Pavlicek. In July 2023, Novartis acquired DTx Pharma, Inc. for USD 500 million, including an additional USD 500 million on achievement of pre-specified milestones. The company provides a FALCON platform (Fatty Acid Ligand Conjugated OligoNucleotide) that enables the delivery of RNA therapeutics for neuromuscular diseases.'s CMT1A therapeutic program and the FALCON platform.
Who invested in DTx Pharma
12 investors across 3 rounds
See all investors in DTx Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about DTx Pharma
Who invested in DTx Pharma?
DTx Pharma has 12 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has DTx Pharma raised?
DTx Pharma has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did DTx Pharma last raise money?
DTx Pharma's most recent round on record is a Series B, in Feb 2021.
What does DTx Pharma do?
Based in California, US, and founded in 2017, DTx Pharma, Inc.
Where is DTx Pharma headquartered?
DTx Pharma is headquartered in San Diego, US.
Which VCs invest in companies like DTx Pharma?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at DTx Pharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like DTx Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.